Why the study?
Does aspirin 300 mg or 1200 mg daily alter coagulation, fibrinolytic, and platelet function compared to placebo in patients with transient ischaemic attacks?
Population
49 patients with transient ischaemic attacks
Comparison
Aspirin 300 mg or 1,200 mg daily for between 9… vs Placebo
Design
RCT, Randomly allocated
Follow-up
9 months to 4 years
Authors
Loading...
300 mg aspirin matches 1200 mg for platelet inhibition with less blood loss; supports lower-dose preference in TIA practice and trials.
Does aspirin 300 mg or 1200 mg daily alter coagulation, fibrinolytic, and platelet function compared to placebo in patients with transient ischaemic attacks?
Aspirin 300 mg and 1200 mg daily provide equivalent platelet inhibition, but the 1200 mg dose is associated with greater gastrointestinal blood loss.
Hampton et al. (1990) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: